Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.34 |
| ▸ | LIPE | Q05469 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14038064 | 1.00 | EGFR (0.38) | EGFRLMNACYP2C9TSHRAPEX1 | |
| SCHEMBL3670014 | 0.83 | ALPL (0.36) | EGFRALPLUCHL1AAK1 | |
| SCHEMBL30132973 | 0.83 | ALPL (0.36) | EGFRALPLUCHL1AAK1 | |
| SCHEMBL2453019 | 0.81 | LPL (0.36) | EGFRALPLUCHL1LIPEAAK1 | |
| SCHEMBL23658807 | 0.79 | UCHL1 (0.40) | EGFRALPLUCHL1AAK1 | |
| SCHEMBL15923768 | 0.79 | EGFR (0.33) | EGFRUCHL1LIPE | |
| SCHEMBL15817447 | 0.79 | EGFR (0.37) | EGFRLIPEBACE1 | |
| SCHEMBL23658912 | 0.78 | KMT2A (0.40) | LMNASMN1; SMN2ALPLLIPEAAK1 | |
| SCHEMBL23647744 | 0.77 | PDGFRB (0.36) | EGFRALPL | |
| SCHEMBL18224565 | 0.77 | ALPL (0.40) | ALPLUCHL1PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220396578-A1 | QUINOXALINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2022-12-15 | — | — | US | disclosed |
| US-20220372041-A1 | QUINOXALINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2022-11-24 | — | — | US | disclosed |
| EP-4090660-A1 | QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2022-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396578-A1 | QUINOXALINE DERIVATIVES | NR3C1, NR3C2, GRK5 | EGFR 4212/4885LMNA 3854/4885CYP2C9 408/4885 |
| US-20220372041-A1 | QUINOXALINE DERIVATIVES | NR3C1, NR3C2, GRK5 | EGFR 4212/4885LMNA 3854/4885CYP2C9 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.